01—Abstract
Summary
Summary of the 10-Q filed October 23, 2025. Cited figures are marked; the original filing is the authoritative source.
West Pharmaceutical Services, Inc. reported third-quarter 2025 net sales of $804.6 milliona, up from $746.9 million a year earlier, with the filing stating an organic increase of 5.0%.
Net income was $140.0 millionb, or $1.92 per diluted share, compared with $136.0 million, or $1.85 per diluted share, in the prior-year quarter. Operating profit rose to $167.6 million from $161.3 million. For the nine months, net sales were $2,269.1 million and net income was $361.6 million, or $4.97 per diluted share, compared with $362.6 million, or $4.91 per diluted share, a year earlier.
Results for the nine months were affected by $21.9 millionc of restructuring and related charges tied to the 2025 restructuring plan and the optimization of the legal structure of the Company and its subsidiaries. Cash flow from operations for the nine months was $503.7 million, up from $463.3 million. Capital expenditures fell to $209.8 million from $272.1 million, and share repurchases totaled $134.0 million, compared with $506.5 million in the prior-year period.
Cash and cash equivalents were $628.5 milliond at September 30, 2025, and total debt was $202.7 million. The company had no outstanding borrowings under its $500.0 million multi-currency revolving credit facility, and it stated that it was in compliance with all debt covenants.
The filing also discloses a securities class action filed May 5, 2025 in the U.S. District Court for the Eastern District of Pennsylvania, alleging violations of the Securities Exchange Act related to public statements and insider transactions. The company states it is unable to predict the outcome or estimate a range of potential loss.
02—Key points
Key Highlights
- Third-quarter net sales rose to $804.6 million from $746.9 million, with the filing stating an organic increase of 5.0%.
- Third-quarter diluted EPS was $1.92, compared with $1.85 a year earlier; net income was $140.0 million versus $136.0 million.
- Nine-month net income was $361.6 million, roughly flat with $362.6 million, as restructuring and related charges totaled $21.9 million in the period.
- Proprietary Products segment net sales were $647.5 million in the quarter, up from $601.4 million, and Contract-Manufactured Products net sales were $157.1 million, up from $145.5 million.
- Cash flow from operating activities was $503.7 million for the nine months, versus $463.3 million; capital expenditures fell to $209.8 million from $272.1 million.
- Share repurchases totaled $134.0 million for the nine months, compared with $506.5 million a year earlier; the company did not repurchase shares in the third quarter.
- A securities class action filed May 5, 2025 remains in early stages, and the company states it cannot predict the outcome or estimate a potential loss.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2025, West Pharmaceutical Services kept $0.17.
- Revenue$804.6M100.0%
- Cost of revenue−$510.3M63.4%
- Gross profit$294.3M36.6%
- Operating costs−$126.7M15.7%
- Operating income$167.6M20.8%
- Interest, other & tax−$27.6M3.4%
- Net income$140.0M17.4%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2025filed October 23, 2025Financial Statements
Q3 FY2025 against Q3 FY2024
| Line item | Q3 FY2025Q3 FY2024 | Change |
|---|---|---|
| Revenue | $804.60M$746.90M | +7.7% |
| Cost of Revenue | $510.30M$482.20M | +5.8% |
| Gross Profit | $294.30M$264.70M | +11.2% |
| R&D Expenses | $17.10M$15.50M | +10.3% |
| SG&A Expenses | $102.70M$83.50M | +23.0% |
| Operating Income | $167.60M$161.30M | +3.9% |
| Net Income | $140.00M$136.00M | +2.9% |
| EPS (Basic) | $1.94$1.87 | +3.7% |
| EPS (Diluted) | $1.92$1.85 | +3.8% |
| Shares Outstanding (Basic) | 72.20M72.80M | −0.8% |
| Shares Outstanding (Diluted) | 72.60M73.40M | −1.1% |
05—Questions
Frequently Asked Questions
How did West Pharmaceutical perform in the third quarter of 2025?
Net sales were $804.6 million, up from $746.9 million, and net income was $140.0 million, or $1.92 per diluted share, compared with $1.85 a year earlier. Operating profit was $167.6 million, versus $161.3 million. The filing states that organic net sales growth was 5.0%.
What drove segment performance?
Proprietary Products net sales increased to $647.5 million from $601.4 million, driven primarily by Westar, Envision and NovaBrand products, partly offset by a decline in self-injection device platforms and about $19 million in customer incentives from the prior-year period that did not recur. Contract-Manufactured Products net sales rose to $157.1 million from $145.5 million, due mainly to self-injection devices for obesity and diabetes.
How much cash does the company have and how is it being used?
Cash and cash equivalents were $628.5 million at September 30, 2025, up from $484.6 million at December 31, 2024. For the nine months, the company generated $503.7 million from operating activities, spent $209.8 million on capital expenditures, paid $45.4 million in dividends and repurchased $134.0 million of shares. Debt was $202.7 million, and the $500.0 million revolving credit facility was undrawn.
What are the main legal risks disclosed?
A securities class action was filed on May 5, 2025 in the U.S. District Court for the Eastern District of Pennsylvania on behalf of investors who acquired the stock between February 16, 2023 and February 12, 2025. The complaint alleges violations of the Securities Exchange Act related to public statements and certain officers' stock transactions. The company intends to vigorously defend the case and states it cannot predict the outcome or estimate a range of potential loss.
What restructuring activity affected results this year?
In January 2025 the company approved a restructuring plan with expected charges of approximately $30 million to $32 million and annualized savings of $35 million to $40 million. Restructuring and related charges were $17.5 million in other expense for the nine months, and $21.9 million total across the restructuring programs including legal structure optimization charges.
06—Continue